AAAAAA

   
Results: 1-8 |
Results: 8
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial (vol 85, pg 4118, 2000)
Authors: Black, DM Thompson, DE Bauer, DC Ensrud, K Musliner, T Hochberg, MC Nevitt, MC Suryawanshi, S Cummings, SR
Citation: Dm. Black et al., Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial (vol 85, pg 4118, 2000), J CLIN END, 86(2), 2001, pp. 938-938
Vertebral fracture prevalence among women screened for the fracture intervention trial and a simple clinical tool to screen for undiagnosed vertebralfractures
Authors: Vogt, TM Ross, PD Palermo, L Musliner, T Genant, HK Black, D Thompson, DE
Citation: Tm. Vogt et al., Vertebral fracture prevalence among women screened for the fracture intervention trial and a simple clinical tool to screen for undiagnosed vertebralfractures, MAYO CLIN P, 75(9), 2000, pp. 888-896
Alendronate and estrogen effects in postmenopausal women with low bone mineral density
Authors: Bone, HG Greenspan, SL McKeever, C Bell, N Davidson, M Downs, RW Emkey, R Meunier, PJ Miller, SS Mulloy, AL Recker, RR Weiss, SR Heyden, N Musliner, T Suryawanshi, S Yates, AJ Lombardi, A
Citation: Hg. Bone et al., Alendronate and estrogen effects in postmenopausal women with low bone mineral density, J CLIN END, 85(2), 2000, pp. 720-726
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
Authors: Black, DM Thompson, DE Bauer, DC Ensrud, K Musliner, T Hochberg, MC Nevitt, MC Suryawanshi, S Cummings, SR
Citation: Dm. Black et al., Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial, J CLIN END, 85(11), 2000, pp. 4118-4124
Upper gastrointestinal tract safety profile of alendronate - The Fracture Intervention Trial
Authors: Bauer, DC Black, D Ensrud, K Thompson, D Hochberg, M Nevitt, M Musliner, T Freedholm, D
Citation: Dc. Bauer et al., Upper gastrointestinal tract safety profile of alendronate - The Fracture Intervention Trial, ARCH IN MED, 160(4), 2000, pp. 517-525
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae
Authors: Lanza, F Schwartz, H Sahba, B Malaty, HM Musliner, T Reyes, R Quan, H Graham, DY
Citation: F. Lanza et al., An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae, AM J GASTRO, 95(11), 2000, pp. 3112-3117
Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: Effect of number and spinal location of fractures
Authors: Nevitt, MC Ross, PD Palermo, L Musliner, T Genant, HK Thompson, DE
Citation: Mc. Nevitt et al., Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: Effect of number and spinal location of fractures, BONE, 25(5), 1999, pp. 613-619
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
Authors: Hochberg, MC Ross, PD Black, D Cummings, SR Genant, HK Nevitt, MC Barret-Connor, E Musliner, T Thompson, D
Citation: Mc. Hochberg et al., Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis, ARTH RHEUM, 42(6), 1999, pp. 1246-1254
Risultati: 1-8 |